Cochrane · systematic review · CD012930
Once daily long‐acting beta2‐agonists and long‐acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease
Maqsood, U, Ho, TN, Palmer, K, et al. · Cochrane Database of Systematic Reviews · 2019 · Cochrane Library
AirwaysAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
7
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 1 · 14.3%Moderate 3 · 42.9%High 3 · 42.9%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Once‐daily LABA/LAMA in a combined inhaler compared with placebo in adults with COPD
Population: Adults with COPD
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality (3‐week to 1‐year Once‐daily LABA/LAMA in a combined inhaler vs placebo | OR 1.88 [0.81, 4.36] | 18 studies · 8752 participants | Low Downgraded: indirectness |
Serious adverse events (3‐week to 1‐year Once‐daily LABA/LAMA in a combined inhaler vs placebo | OR 1.06 [0.88, 1.28] | 22 studies · 10536 participants | High |
Acute exacerbations of COPD (4‐week to 24‐week Once‐daily LABA/LAMA in a combined inhaler vs placebo | OR 0.53 [0.36, 0.78] | 3 studies · 1127 participants | Moderate Downgraded: imprecision, inconsistency, indirectness |
Difference vs placebo in adjusted SGRQ score (HRQoL) Scale 0‐100, lower on the scale is better. (12‐week to 1‐year Once‐daily LABA/LAMA in a combined inhaler vs placebo | no estimate extracted | 8 studies · 4952 participants | High |
Difference vs placebo in adjusted trough FEV1 at EOT (3‐week to 1‐year Once‐daily LABA/LAMA in a combined inhaler vs placebo | no estimate extracted | 13 studies · 6598 participants | Moderate Downgraded: imprecision, inconsistency, indirectness |
Difference vs placebo in adjusted peak FEV1 (3‐week to 6‐month Once‐daily LABA/LAMA in a combined inhaler vs placebo | no estimate extracted | 7 studies · 4188 participants | Moderate Downgraded: imprecision, inconsistency, indirectness |
Adverse events (3‐week to 1‐year Once‐daily LABA/LAMA in a combined inhaler vs placebo | OR 0.95 [0.86, 1.04] | 17 studies · 8235 participants | High |